Association of injury after prescription opioid initiation with risk for opioid-related adverse events among older Medicare beneficiaries in the United States: A nested case-control study.
Journal
PLoS medicine
ISSN: 1549-1676
Titre abrégé: PLoS Med
Pays: United States
ID NLM: 101231360
Informations de publication
Date de publication:
09 2022
09 2022
Historique:
received:
18
04
2022
accepted:
25
08
2022
entrez:
22
9
2022
pubmed:
23
9
2022
medline:
28
9
2022
Statut:
epublish
Résumé
Injury, prevalent and potentially associated with prescription opioid use among older adults, has been implicated as a warning sign of serious opioid-related adverse events (ORAEs) including opioid misuse, dependence, and poisoning, but this association has not been empirically tested. The study aims to examine the association between incident injury after prescription opioid initiation and subsequent risk of ORAEs and to assess whether the association differs by recency of injury among older patients. This nested case-control study was conducted within a cohort of 126,752 individuals aged 65 years or older selected from a 5% sample of Medicare beneficiaries in the United States between 2011 and 2018. Cohort participants were newly prescribed opioid users with chronic noncancer pain who had no injury or ORAEs in the year before opioid initiation, had 30 days or more of observation, and had at least 1 additional opioid prescription dispensed during follow-up. We identified ORAE cases as patients who had an inpatient or outpatient encounter with diagnosis codes for opioid misuse, dependence, or poisoning. During a mean follow-up of 1.8 years, we identified 2,734 patients who were newly diagnosed with ORAEs and 10,936 controls matched on the year of cohort entry date and a disease risk score (DRS), a summary score derived from the probability of an ORAE outcome based on covariates measured prior to cohort entry and in the absence of injury. Multivariate conditional logistic regression was used to estimate ORAE risk associated with any and recency of injury, defined based on the primary diagnosis code of inpatient and outpatient encounters. Among the cases and controls, 68.0% (n = 1,859 for cases and n = 7,436 for controls) were women and the mean (SD) age was 74.5 (6.9) years. Overall, 54.0% (n = 1,475) of cases and 46.0% (n = 1,259) of controls experienced incident injury after opioid initiation. Patients with (versus without) injury after opioid therapy had higher risk of ORAEs after adjustment for time-varying confounders, including diagnosis of tobacco or alcohol use disorder, drug use disorder, chronic pain diagnosis, mental health disorder, pain-related comorbidities, frailty index, emergency department visit, skilled nursing facility stay, anticonvulsant use, and patterns of prescription opioid use (adjusted odds ratio [aOR] = 1.4; 95% confidence interval (CI) 1.2 to 1.5; P < 0.001). Increased risk of ORAEs was associated with current (≤30 days) injury (aOR = 2.8; 95% CI 2.3 to 3.4; P < 0.001), whereas risk of ORAEs was not significantly associated with recent (31 to 90 days; aOR = 0.93; 95% CI 0.73 to 1.17; P = 0.48), past (91 to 180 days; aOR = 1.08; 95% CI 0.88 to 1.33; P = 0.51), and remote (181 to 365 days; aOR = 0.88; 95% CI 0.73 to 1.1; P = 0.18) injury preceding the incident diagnosis of ORAE or matched date. Patients with injury and prescription opioid use versus those with neither in the month before the ORAE or matched date were at greater risk of ORAEs (aOR = 5.0; 95% CI 4.1 to 6.1; P < 0.001). Major limitations are that the study findings can only be generalized to older Medicare fee-for-service beneficiaries and that unknown or unmeasured confounders have the potential to bias the observed association toward or away from the null. In this study, we observed that incident diagnosis of injury following opioid initiation was associated with subsequent increased risk of ORAEs, and the risk was only significant among patients with injury in the month before the index date. Regular monitoring for injury may help identify older opioid users at high risk for ORAEs.
Sections du résumé
BACKGROUND
Injury, prevalent and potentially associated with prescription opioid use among older adults, has been implicated as a warning sign of serious opioid-related adverse events (ORAEs) including opioid misuse, dependence, and poisoning, but this association has not been empirically tested. The study aims to examine the association between incident injury after prescription opioid initiation and subsequent risk of ORAEs and to assess whether the association differs by recency of injury among older patients.
METHODS AND FINDINGS
This nested case-control study was conducted within a cohort of 126,752 individuals aged 65 years or older selected from a 5% sample of Medicare beneficiaries in the United States between 2011 and 2018. Cohort participants were newly prescribed opioid users with chronic noncancer pain who had no injury or ORAEs in the year before opioid initiation, had 30 days or more of observation, and had at least 1 additional opioid prescription dispensed during follow-up. We identified ORAE cases as patients who had an inpatient or outpatient encounter with diagnosis codes for opioid misuse, dependence, or poisoning. During a mean follow-up of 1.8 years, we identified 2,734 patients who were newly diagnosed with ORAEs and 10,936 controls matched on the year of cohort entry date and a disease risk score (DRS), a summary score derived from the probability of an ORAE outcome based on covariates measured prior to cohort entry and in the absence of injury. Multivariate conditional logistic regression was used to estimate ORAE risk associated with any and recency of injury, defined based on the primary diagnosis code of inpatient and outpatient encounters. Among the cases and controls, 68.0% (n = 1,859 for cases and n = 7,436 for controls) were women and the mean (SD) age was 74.5 (6.9) years. Overall, 54.0% (n = 1,475) of cases and 46.0% (n = 1,259) of controls experienced incident injury after opioid initiation. Patients with (versus without) injury after opioid therapy had higher risk of ORAEs after adjustment for time-varying confounders, including diagnosis of tobacco or alcohol use disorder, drug use disorder, chronic pain diagnosis, mental health disorder, pain-related comorbidities, frailty index, emergency department visit, skilled nursing facility stay, anticonvulsant use, and patterns of prescription opioid use (adjusted odds ratio [aOR] = 1.4; 95% confidence interval (CI) 1.2 to 1.5; P < 0.001). Increased risk of ORAEs was associated with current (≤30 days) injury (aOR = 2.8; 95% CI 2.3 to 3.4; P < 0.001), whereas risk of ORAEs was not significantly associated with recent (31 to 90 days; aOR = 0.93; 95% CI 0.73 to 1.17; P = 0.48), past (91 to 180 days; aOR = 1.08; 95% CI 0.88 to 1.33; P = 0.51), and remote (181 to 365 days; aOR = 0.88; 95% CI 0.73 to 1.1; P = 0.18) injury preceding the incident diagnosis of ORAE or matched date. Patients with injury and prescription opioid use versus those with neither in the month before the ORAE or matched date were at greater risk of ORAEs (aOR = 5.0; 95% CI 4.1 to 6.1; P < 0.001). Major limitations are that the study findings can only be generalized to older Medicare fee-for-service beneficiaries and that unknown or unmeasured confounders have the potential to bias the observed association toward or away from the null.
CONCLUSIONS
In this study, we observed that incident diagnosis of injury following opioid initiation was associated with subsequent increased risk of ORAEs, and the risk was only significant among patients with injury in the month before the index date. Regular monitoring for injury may help identify older opioid users at high risk for ORAEs.
Identifiants
pubmed: 36136971
doi: 10.1371/journal.pmed.1004101
pii: PMEDICINE-D-22-01302
pmc: PMC9498946
doi:
Substances chimiques
Analgesics, Opioid
0
Anticonvulsants
0
Types de publication
Journal Article
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1004101Subventions
Organisme : AHRQ HHS
ID : R03 HS027230
Pays : United States
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Lancet Psychiatry. 2022 Feb;9(2):151-159
pubmed: 34921800
Stat Methods Med Res. 2009 Feb;18(1):67-80
pubmed: 18562398
JAMA Netw Open. 2019 Aug 2;2(8):e199679
pubmed: 31433480
JAMA Netw Open. 2020 Sep 1;3(9):e2015909
pubmed: 32886123
Innov Aging. 2019 Mar 07;3(1):igz002
pubmed: 30863796
Ann Intern Med. 2010 Jan 19;152(2):85-92
pubmed: 20083827
Am J Epidemiol. 2016 May 15;183(10):949-57
pubmed: 27189330
Prev Chronic Dis. 2019 Nov 27;16:E157
pubmed: 31775008
Annu Rev Public Health. 2000;21:193-221
pubmed: 10884952
BMC Health Serv Res. 2017 Apr 26;17(1):304
pubmed: 28446159
Pharmacoepidemiol Drug Saf. 2017 May;26(5):509-517
pubmed: 28074520
Am J Epidemiol. 2018 Nov 1;187(11):2439-2448
pubmed: 29947726
Stat Med. 2019 Sep 30;38(22):4209-4212
pubmed: 31489683
Inj Epidemiol. 2019 Mar 25;6:11
pubmed: 31245260
Prev Med. 2018 Jul;112:176-178
pubmed: 29684417
PLoS Med. 2019 Nov 5;16(11):e1002941
pubmed: 31689302
Stat Med. 2009 Nov 10;28(25):3083-107
pubmed: 19757444
J Gerontol A Biol Sci Med Sci. 2021 Jun 14;76(7):1316-1317
pubmed: 32529241
Occup Environ Med. 2004 Dec;61(12):e59
pubmed: 15550597
MMWR Morb Mortal Wkly Rep. 2020 Mar 20;69(11):298-302
pubmed: 32191686
Int J Geriatr Psychiatry. 2017 Apr;32(4):414-420
pubmed: 27113813
JAMA. 2018 Nov 27;320(20):2067
pubmed: 30480710
J Am Geriatr Soc. 2010 Sep;58(9):1664-70
pubmed: 20863326
CMAJ. 2018 Apr 23;190(16):E500-E506
pubmed: 29685910
BMJ. 2015 Feb 13;350:h532
pubmed: 25680884
Natl Health Stat Report. 2020 Dec;(150):1-27
pubmed: 33395385
J Gerontol A Biol Sci Med Sci. 2018 Jun 14;73(7):980-987
pubmed: 29244057
J Am Geriatr Soc. 2011 Mar;59(3):430-8
pubmed: 21391934
MMWR Recomm Rep. 1997 Aug 29;46(RR-14):1-30
pubmed: 9301976
Epidemiology. 1994 Sep;5(5):541-4
pubmed: 7986870
Drug Alcohol Depend. 2019 Nov 1;204:107600
pubmed: 31586806
Ann Intern Med. 2015 Feb 17;162(4):276-86
pubmed: 25581257
Inj Prev. 2017 Apr;23(2):87-92
pubmed: 27597400
JACC Cardiovasc Interv. 2020 Aug 10;13(15):1786-1788
pubmed: 32682675